Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Biopharma industry accelerates attacks on Trump

Pfizer’s Bourla pushes back on pricing index plan as BIO’s McMurry-Heath calls out ‘conspiracy’ theory tweet

Last week the White House invited Pfizer Chairman and CEO Albert Bourla to join a group of his peers at the White House Tuesday to discuss drug pricing with President Donald Trump. Instead of traveling to Washington, the executive participated in an earnings call in which he countered Trump’s threat to impose a “most favored nation” policy on Medicare Part B drug purchases.

Bourla’s peers also declined to participate in the meeting, convinced that Trump was not negotiating

Read the full 786 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers